Putting the award page together from the records…
Putting the award page together from the records…
Public Health Vaccines LLC received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $66.24M obligated so far for health r&d services; health care services; experimental development. It runs to 2029-01-31.
Key facts · data as of Oct 22, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50119C00022, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50119C00022_7505_-NONE-_-NONE-
Public Health Vaccines LLC: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE.
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
13 actions since 2023-03-21. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-06-08 | P00026 | Option exercised | $33.48M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 6. |
| 2026-01-16 | P00025 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0004/OPTION 3 TO APRIL 30, 2026, TO ALIGN WITH IPP. |
| 2025-09-24 | P00024 | Option exercised | $19.46M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 4/CLIN00005 |
| 2025-03-11 | P00023 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - UPDATE POP |
| 2024-11-18 | P00022 | Administrative change | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - ADMIN MOD |
| 2024-09-25 | P00021 | Supplemental agreement (work within scope) | $7.49M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. - SUPPLEMENTAL FUNDING MOD |
| 2024-05-28 | P00020 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2024-02-29 | P00019 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2023-12-13 | P00018 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2023-11-02 | P00017 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2023-09-21 | P00016 | Supplemental agreement (work within scope) | $5.82M | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2023-04-25 | P00015 | Administrative change | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
| 2023-03-21 | P00014 | Supplemental agreement (work within scope) | $0 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗